Enveric Biosciences receives notice of allowance from USPTO for its drug candidate EB-003 to treat mental health disorders: Cambridge, Massachusetts Saturday, February 1, 2025, 13 ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Tryptamine Therapeutics Ltd (ASX ... “It further validates Tryp’s approach to drug development and also serves as a ...

Tryptamine is focused on the development of an IV-infused psilocin solution which can be used with therapy to address unmet medical needs. The company said its lead asset TRP-8803 aimed to ...

“Looking ahead, we are excited about Cybin’s next phase of investigation and growth and for the upcoming milestones, including a readout of topline efficacy data from our CYB004 Phase 2 GAD study in ...

Psychedelics gained notoriety as recreational drugs, but they are now part of ... a naturally occurring tryptamine compound found in the psychoactive psilocybe genus of mushrooms.